HCA Healthcare, Inc. $HCA is Lawson Kroeker Investment Management Inc. NE’s 6th Largest Position

Lawson Kroeker Investment Management Inc. NE lowered its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,465 shares of the company’s stock after selling 232 shares during the period. HCA Healthcare makes up approximately 3.7% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 6th largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in HCA Healthcare were worth $20,099,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its holdings in HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after buying an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of HCA Healthcare by 49.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after acquiring an additional 587,036 shares during the period. Nuveen LLC purchased a new stake in HCA Healthcare in the first quarter worth approximately $569,217,000. Pacer Advisors Inc. raised its stake in HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after buying an additional 1,329,618 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of HCA Healthcare by 0.8% in the 1st quarter. Principal Financial Group Inc. now owns 880,663 shares of the company’s stock worth $304,313,000 after buying an additional 6,888 shares during the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Analyst Upgrades and Downgrades

HCA has been the topic of several research reports. Royal Bank Of Canada dropped their target price on HCA Healthcare from $404.00 to $401.00 and set an “outperform” rating on the stock in a research report on Monday, July 28th. Barclays raised their price objective on shares of HCA Healthcare from $390.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Truist Financial lifted their price target on shares of HCA Healthcare from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, July 16th. KeyCorp raised their target price on HCA Healthcare from $370.00 to $465.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $444.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $422.31.

HCA Healthcare Stock Down 1.0%

NYSE HCA opened at $414.73 on Friday. The business has a 50-day moving average price of $405.12 and a 200-day moving average price of $375.85. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $439.01. The firm has a market cap of $97.04 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 1.31 and a beta of 1.40.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.20 by $0.64. The business had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were issued a $0.72 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare’s payout ratio is 12.11%.

Insider Activity at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company’s stock.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.